Xue-Min Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xue-Min Zhang has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
Kun He
National Center of Biomedical Analysis , 27 Taiping Road, Beijing 100039, China
8 shared publicationsMing Yu
Institute of Basic Medical Sciences, National Center of Biomedical Analysis, Tai-Ping Road 27, Beijing 100850, China
7 shared publicationsTao Zhou
Institute of Basic Medical Sciences State Key Laboratory of Proteomics National Center of Biomedical Analysis Beijing China
7 shared publicationsJie Wang
Institute of Basic Medical Sciences, National Center of Biomedical Analysis, Beijing, China
6 shared publicationsBao-Feng Jin
Institute of Basic Medical Sciences State Key Laboratory of Proteomics National Center of Biomedical Analysis Beijing China
5 shared publicationsHui-Yan Li
Institute of Basic Medical Sciences State Key Laboratory of Proteomics National Center of Biomedical Analysis Beijing China
5 shared publications
Latest Publications
- Open Access
- 18 November 2022
- Published by KEAI Publishing in Fundamental Research
- Vol. 2 (6) , 827-828
Opportunities and challenges of rare and undiagnosed disease research in China
- 18 November 2022
- Published by KEAI Publishing in Fundamental Research
- Vol. 2 (6) , 827-828
Open AccessOpportunities and challenges of rare and undiagnosed disease research in China
- 16 November 2011
- Published by Elsevier in Current Opinion in Biotechnology
- Vol. 23 (1) , 120-125
Mass spectrometry-based signal networks elucidation
- 16 November 2011
- Published by Elsevier in Current Opinion in Biotechnology
- Vol. 23 (1) , 120-125
Mass spectrometry-based signal networks elucidation
- 1 September 2011
- Published by Oxford University Press (OUP) in Protein & Cell
- Vol. 2 (9) , 699-703
CUEDC2: an emerging key player in inflammation and tumorigenesis
CUE domain-containing 2 (CUEDC2) is a protein involved in the regulation of the cell cycle, inflammation, and tumorigenesis and is highly expressed in many types of tumors. CUEDC2 is phosphorylated by Cdk1 during mitosis and promotes the release of anaphase-promoting complex or cyclosome (APC/C) from checkpoint inhibition. CUEDC2 is also known to interact with IkB kinase α (IKKα) and IKKβ and has an inhibitory role in the activation of transcription factor nuclear factor-κB. Moreover, CUEDC2 plays an important role in downregulating the expression of hormone receptors estrogen receptor-α and progesterone receptor, thereby impairing the responsiveness of breast cancer to endocrine therapies. In this review, current knowledge on the multi-functions of CUEDC2 in normal processes and tumorigenesis are discussed and summarized.
- 1 September 2011
- Published by Oxford University Press (OUP) in Protein & Cell
- Vol. 2 (9) , 699-703
CUEDC2: an emerging key player in inflammation and tumorigenesis
CUE domain-containing 2 (CUEDC2) is a protein involved in the regulation of the cell cycle, inflammation, and tumorigenesis and is highly expressed in many types of tumors. CUEDC2 is phosphorylated by Cdk1 during mitosis and promotes the release of anaphase-promoting complex or cyclosome (APC/C) from checkpoint inhibition. CUEDC2 is also known to interact with IkB kinase α (IKKα) and IKKβ and has an inhibitory role in the activation of transcription factor nuclear factor-κB. Moreover, CUEDC2 plays an important role in downregulating the expression of hormone receptors estrogen receptor-α and progesterone receptor, thereby impairing the responsiveness of breast cancer to endocrine therapies. In this review, current knowledge on the multi-functions of CUEDC2 in normal processes and tumorigenesis are discussed and summarized.
- Open Access
- 2 August 2010
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 120 (8) , 2829-2841
Gankyrin plays an essential role in Ras-induced tumorigenesis through regulation of the RhoA/ROCK pathway in mammalian cells
Activating mutations in Ras proteins are present in about 30% of human cancers. Despite tremendous progress in the study of Ras oncogenes, many aspects of the molecular mechanisms underlying Ras-induced tumorigenesis remain unknown. Through proteomics analysis, we previously found that the protein Gankyrin, a known oncoprotein in hepatocellular carcinoma, was upregulated during Ras-mediated transformation, although the functional consequences of this were not clear. Here we present evidence that Gankyrin plays an essential role in Ras-initiated tumorigenesis in mouse and human cells. We found that the increased Gankyrin present following Ras activation increased the interaction between the RhoA GTPase and its GDP dissociation inhibitor RhoGDI, which resulted in inhibition of the RhoA effector kinase Rho-associated coiled coil–containing protein kinase (ROCK). Importantly, Gankyrin-mediated ROCK inhibition led to prolonged Akt activation, a critical step in activated Ras–induced transformation and tumorigenesis. In addition, we found that Gankyrin is highly expressed in human lung cancers that have Ras mutations and that increased Gankyrin expression is required for the constitutive activation of Akt and tumorigenesis in these lung cancers. Our findings suggest that Gankyrin is a key regulator of Ras-mediated activation of Akt through inhibition of the downstream RhoA/ROCK pathway and thus plays an essential role in Ras-induced tumorigenesis.
- 2 August 2010
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 120 (8) , 2829-2841
Open AccessGankyrin plays an essential role in Ras-induced tumorigenesis through regulation of the RhoA/ROCK pathway in mammalian cells
Activating mutations in Ras proteins are present in about 30% of human cancers. Despite tremendous progress in the study of Ras oncogenes, many aspects of the molecular mechanisms underlying Ras-induced tumorigenesis remain unknown. Through proteomics analysis, we previously found that the protein Gankyrin, a known oncoprotein in hepatocellular carcinoma, was upregulated during Ras-mediated transformation, although the functional consequences of this were not clear. Here we present evidence that Gankyrin plays an essential role in Ras-initiated tumorigenesis in mouse and human cells. We found that the increased Gankyrin present following Ras activation increased the interaction between the RhoA GTPase and its GDP dissociation inhibitor RhoGDI, which resulted in inhibition of the RhoA effector kinase Rho-associated coiled coil–containing protein kinase (ROCK). Importantly, Gankyrin-mediated ROCK inhibition led to prolonged Akt activation, a critical step in activated Ras–induced transformation and tumorigenesis. In addition, we found that Gankyrin is highly expressed in human lung cancers that have Ras mutations and that increased Gankyrin expression is required for the constitutive activation of Akt and tumorigenesis in these lung cancers. Our findings suggest that Gankyrin is a key regulator of Ras-mediated activation of Akt through inhibition of the downstream RhoA/ROCK pathway and thus plays an essential role in Ras-induced tumorigenesis.
- 1 July 2010
- Published by Springer Nature in Science-Business eXchange
- Vol. 3 (29) , 889
Proteasome (prosome macropain) 26S subunit non-ATPase 10 (PSMD10; gankyrin)
- 1 July 2010
- Published by Springer Nature in Science-Business eXchange
- Vol. 3 (29) , 889
Proteasome (prosome macropain) 26S subunit non-ATPase 10 (PSMD10; gankyrin)
- Open Access
- 1 June 2009
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 33 (5) , 272-277
Rapid Detection of Conotoxin SO3 in Serum Using Cu-Chelated Magnetic Beads Coupled with Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry
A novel method based on Cu-chelated magnetic beads (Cu-Magbeads) and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) was developed for the rapid detection of peptide toxins in serum. The peptides in the serum were efficiently adsorbed by the Cu-Magbeads, eluted with methanol solution, and assayed by MALDI-TOF-MS. Specific peptides were identified according to their characteristic mass-to-charge ratio values. Conotoxin SO3, a synthesized peptide, was used as a model to evaluate the method. Conotoxin SO3 was detected in human serum, as well as bovine and murine serum, with a detection sensitivity in the low femtomole range. The assay was performed within 40 min, without the need for a specific antibody or an expensive reagent. It shows potential for future use in clinical and emergency rescue practice because of its simplicity, high speed, and high sensitivity.
- 1 June 2009
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 33 (5) , 272-277
Open AccessRapid Detection of Conotoxin SO3 in Serum Using Cu-Chelated Magnetic Beads Coupled with Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry
A novel method based on Cu-chelated magnetic beads (Cu-Magbeads) and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) was developed for the rapid detection of peptide toxins in serum. The peptides in the serum were efficiently adsorbed by the Cu-Magbeads, eluted with methanol solution, and assayed by MALDI-TOF-MS. Specific peptides were identified according to their characteristic mass-to-charge ratio values. Conotoxin SO3, a synthesized peptide, was used as a model to evaluate the method. Conotoxin SO3 was detected in human serum, as well as bovine and murine serum, with a detection sensitivity in the low femtomole range. The assay was performed within 40 min, without the need for a specific antibody or an expensive reagent. It shows potential for future use in clinical and emergency rescue practice because of its simplicity, high speed, and high sensitivity.
- 10 March 2009
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 106 (10) , 3788-3793
Induction of SOX4 by DNA damage is critical for p53 stabilization and function
DNA damage response (DDR) acts as a tumorigenesis barrier, and any defects in the DDR machinery may lead to cancer. SOX4 expression is elevated in many types of tumors; however, its role in DDR is still largely unknown. Here, we show that SOX4, a new DNA damage sensor, is required for the activation of p53 tumor suppressor in response to DNA damage. Notably, SOX4 interacts with and stabilizes p53 protein by blocking Mdm2-mediated p53 ubiquitination and degradation. Furthermore, SOX4 enhances p53 acetylation by interacting with p300/CBP and facilitating p300/CBP/p53 complex formation. In concert with these results, SOX4 promotes cell cycle arrest and apoptosis, and it inhibits tumorigenesis in a p53-dependent manner. Therefore, these findings highlight SOX4 as a potential key factor in regulating DDR-associated cancer.
- 10 March 2009
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 106 (10) , 3788-3793
Induction of SOX4 by DNA damage is critical for p53 stabilization and function
DNA damage response (DDR) acts as a tumorigenesis barrier, and any defects in the DDR machinery may lead to cancer. SOX4 expression is elevated in many types of tumors; however, its role in DDR is still largely unknown. Here, we show that SOX4, a new DNA damage sensor, is required for the activation of p53 tumor suppressor in response to DNA damage. Notably, SOX4 interacts with and stabilizes p53 protein by blocking Mdm2-mediated p53 ubiquitination and degradation. Furthermore, SOX4 enhances p53 acetylation by interacting with p300/CBP and facilitating p300/CBP/p53 complex formation. In concert with these results, SOX4 promotes cell cycle arrest and apoptosis, and it inhibits tumorigenesis in a p53-dependent manner. Therefore, these findings highlight SOX4 as a potential key factor in regulating DDR-associated cancer.
- Open Access
- 17 February 2009
- Published by Springer Nature in BMC Medical Informatics and Decision Making
- Vol. 9 (1) , 13
BioSunMS: a plug-in-based software for the management of patients information and the analysis of peptide profiles from mass spectrometry
Background: With wide applications of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) and surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS), statistical comparison of serum peptide profiles and management of patients information play an important role in clinical studies, such as early diagnosis, personalized medicine and biomarker discovery. However, current available software tools mainly focused on data analysis rather than providing a flexible platform for both the management of patients information and mass spectrometry (MS) data analysis. Results: Here we presented a plug-in-based software, BioSunMS, for both the management of patients information and serum peptide profiles-based statistical analysis. By integrating all functions into a user-friendly desktop application, BioSunMS provided a comprehensive solution for clinical researchers without any knowledge in programming, as well as a plug-in architecture platform with the possibility for developers to add or modify functions without need to recompile the entire application. Conclusion: BioSunMS provides a plug-in-based solution for managing, analyzing, and sharing high volumes of MALDI-TOF or SELDI-TOF MS data. The software is freely distributed under GNU General Public License (GPL) and can be downloaded from http://sourceforge.net/projects/biosunms/.
- 17 February 2009
- Published by Springer Nature in BMC Medical Informatics and Decision Making
- Vol. 9 (1) , 13
Open AccessBioSunMS: a plug-in-based software for the management of patients information and the analysis of peptide profiles from mass spectrometry
Background: With wide applications of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) and surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS), statistical comparison of serum peptide profiles and management of patients information play an important role in clinical studies, such as early diagnosis, personalized medicine and biomarker discovery. However, current available software tools mainly focused on data analysis rather than providing a flexible platform for both the management of patients information and mass spectrometry (MS) data analysis. Results: Here we presented a plug-in-based software, BioSunMS, for both the management of patients information and serum peptide profiles-based statistical analysis. By integrating all functions into a user-friendly desktop application, BioSunMS provided a comprehensive solution for clinical researchers without any knowledge in programming, as well as a plug-in architecture platform with the possibility for developers to add or modify functions without need to recompile the entire application. Conclusion: BioSunMS provides a plug-in-based solution for managing, analyzing, and sharing high volumes of MALDI-TOF or SELDI-TOF MS data. The software is freely distributed under GNU General Public License (GPL) and can be downloaded from http://sourceforge.net/projects/biosunms/.
- 13 June 2008
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 7 (7) , 2733-2742
Proteomic Analysis Identifies Protein Targets Responsible for Depsipeptide Sensitivity in Tumor Cells
- 13 June 2008
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 7 (7) , 2733-2742
Proteomic Analysis Identifies Protein Targets Responsible for Depsipeptide Sensitivity in Tumor Cells
- 22 May 2007
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 102 (1) , 149-160
Proteomic analysis of cardiomyocytes differentiation in mouse embryonic carcinoma P19CL6 cells
- 22 May 2007
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 102 (1) , 149-160
Proteomic analysis of cardiomyocytes differentiation in mouse embryonic carcinoma P19CL6 cells